AbbVie Ends Rova-T R&D Program in Small-Cell Lung Cancer
August 29 2019 - 09:34AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. (ABBV) on Thursday said it is ending its research
and development program for Rovalpituzumab Tesirine, or Rova-T,
after the investigational antibody-drug conjugate showed no
survival benefit in a phase 3 study in advanced small-cell lung
cancer.
The North Chicago, Ill., biopharmaceutical company said it will
prioritize other development programs within its oncology
pipeline.
AbbVie said an independent data monitoring committee recommended
terminating the study of Rova-T as a first-line maintenance therapy
for advanced small-cell lung cancer due to lack of survival benefit
for patients receiving Rova-T compared with placebo.
Small-cell lung cancer is difficult to treat and accounts for
10% to 15% of all lung cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 29, 2019 09:19 ET (13:19 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024